On October 15, Regeneron Pharmaceuticals rose 3.09% in Regular Trading, trading near $775.635 per share, with turnover of $239 million.
The move was accompanied by new clinical data showing Pasatru delivered sustained benefit through 84 weeks in the Phase 3 OPTIMA trial extension for adults with fibrodysplasia ossificans progressiva, reinforcing the long-term profile of the recently approved rare-disease therapy.
According to the company update, the study enrolled 63 adult patients and 58 completed at least 84 weeks of the double-blind extension phase. Regeneron said Pasatru continued to suppress new heterotopic ossification lesions and reduce disease flare-ups, while both tested doses remained generally well tolerated through week 84, consistent with findings at week 56. The data extend the evidence base behind the FDA approval granted in August for adult FOP and may strengthen investor confidence in the drug’s commercial durability as Regeneron also advances broader global filings.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments